JP2006502115A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502115A5
JP2006502115A5 JP2004521470A JP2004521470A JP2006502115A5 JP 2006502115 A5 JP2006502115 A5 JP 2006502115A5 JP 2004521470 A JP2004521470 A JP 2004521470A JP 2004521470 A JP2004521470 A JP 2004521470A JP 2006502115 A5 JP2006502115 A5 JP 2006502115A5
Authority
JP
Japan
Prior art keywords
compound according
treatment
indol
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004521470A
Other languages
English (en)
Japanese (ja)
Other versions
JP4771356B2 (ja
JP2006502115A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/019548 external-priority patent/WO2004006928A1/en
Publication of JP2006502115A publication Critical patent/JP2006502115A/ja
Publication of JP2006502115A5 publication Critical patent/JP2006502115A5/ja
Application granted granted Critical
Publication of JP4771356B2 publication Critical patent/JP4771356B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004521470A 2002-07-12 2003-07-08 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶 Expired - Fee Related JP4771356B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39597602P 2002-07-12 2002-07-12
US60/395,976 2002-07-12
PCT/US2003/019548 WO2004006928A1 (en) 2002-07-12 2003-07-08 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011033310A Division JP5242718B2 (ja) 2002-07-12 2011-02-18 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶

Publications (3)

Publication Number Publication Date
JP2006502115A JP2006502115A (ja) 2006-01-19
JP2006502115A5 true JP2006502115A5 (cg-RX-API-DMAC7.html) 2006-08-10
JP4771356B2 JP4771356B2 (ja) 2011-09-14

Family

ID=42799191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004521470A Expired - Fee Related JP4771356B2 (ja) 2002-07-12 2003-07-08 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶
JP2011033310A Expired - Fee Related JP5242718B2 (ja) 2002-07-12 2011-02-18 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011033310A Expired - Fee Related JP5242718B2 (ja) 2002-07-12 2011-02-18 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶

Country Status (21)

Country Link
US (2) US8114901B2 (cg-RX-API-DMAC7.html)
EP (1) EP1523313B1 (cg-RX-API-DMAC7.html)
JP (2) JP4771356B2 (cg-RX-API-DMAC7.html)
KR (1) KR100687165B1 (cg-RX-API-DMAC7.html)
CN (1) CN100430058C (cg-RX-API-DMAC7.html)
AU (1) AU2003280958B9 (cg-RX-API-DMAC7.html)
CA (1) CA2393720C (cg-RX-API-DMAC7.html)
DE (1) DE60317675T2 (cg-RX-API-DMAC7.html)
EA (1) EA007463B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055537A (cg-RX-API-DMAC7.html)
ES (1) ES2295605T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20050035B1 (cg-RX-API-DMAC7.html)
IL (1) IL165747A (cg-RX-API-DMAC7.html)
NO (1) NO330254B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ537137A (cg-RX-API-DMAC7.html)
PE (1) PE20040652A1 (cg-RX-API-DMAC7.html)
PL (1) PL373046A1 (cg-RX-API-DMAC7.html)
TW (1) TWI315667B (cg-RX-API-DMAC7.html)
UA (1) UA78801C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004006928A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500065B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US20110009847A1 (en) 2009-03-02 2011-01-13 Seventh Sense Biosystems, Inc. Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
ES2561824T3 (es) 2010-07-16 2016-03-01 Seventh Sense Biosystems, Inc. Ambiente a baja presión para dispositivos de transferencia de fluidos
EP2630121A1 (en) * 2010-09-30 2013-08-28 Wisconsin Alumni Research Foundation (20r,25s)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin d3 in crystalline form
ES2565805T3 (es) 2010-11-09 2016-04-07 Seventh Sense Biosystems, Inc. Sistemas e interfaces para el muestreo de sangre
KR102237667B1 (ko) 2011-04-29 2021-04-12 세븐쓰 센스 바이오시스템즈, 인크. 유체들의 전달 및/또는 수용
CA3028114A1 (en) 2016-06-17 2017-12-21 Universidad De Los Andes Gelatin polymer derived from natural sources of cold-adapted marine species and uses thereof
CN109789141B (zh) * 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625738A1 (de) * 1986-07-30 1988-02-11 Goedecke Ag 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5489608A (en) * 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
SE501711C2 (sv) * 1993-09-08 1995-05-02 Jimek Int Ab Sprayrör för en duktvättanordning vid en tryckpress
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
AU1189201A (en) 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
JP2005531609A (ja) * 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体

Similar Documents

Publication Publication Date Title
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MXPA03012004A (es) Derivados de aminonicotinato como moduladores de glucocinasa (glk).
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
TW200512200A (en) Carbonyl compounds
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
PT2139483E (pt) Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
TW200504012A (en) Ethynylproline derivatives
MX272108B (es) Heterociclos sustituidos.
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
BRPI0416690A (pt) derivados de pirrol
NO20074360L (no) Behandling av metastaterte tumorer
NO20050428L (no) Arylkarbonylpiperaziner og heteroarylkarbonylpiperaziner og anvendelse derav for behandling av godartede og ondartede tumorsykdommer
CA2393720A1 (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
JP2008524329A5 (cg-RX-API-DMAC7.html)
WO2006084197A3 (en) Nitroxides for use in treating or preventing neoplastic disease
WO2006125555A3 (de) Chinazolinone
IL206397A (en) Cytotoxic substances, preparations containing these substances and their use in the treatment of tumors